Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Depreciation & Amortization (CF) (2020 - 2026)

Neuroone Medical Technologies filings provide 7 years of Depreciation & Amortization (CF) readings, the most recent being $60029.0 for Q1 2026.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 8.54% to $60029.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $256470.0, a 0.59% decrease, with the full-year FY2025 number at $261679.0, up 6.03% from a year prior.
  • Depreciation & Amortization (CF) hit $60029.0 in Q1 2026 for Neuroone Medical Technologies, down from $65523.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $66594.0 in Q2 2025 to a low of $28531.0 in Q1 2022.
  • Median Depreciation & Amortization (CF) over the past 5 years was $60900.0 (2024), compared with a mean of $54514.5.
  • Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 87.03% in 2023 and later decreased 8.54% in 2026.
  • Neuroone Medical Technologies' Depreciation & Amortization (CF) stood at $35889.0 in 2022, then soared by 63.44% to $58657.0 in 2023, then grew by 11.03% to $65127.0 in 2024, then grew by 0.61% to $65523.0 in 2025, then fell by 8.38% to $60029.0 in 2026.
  • The last three reported values for Depreciation & Amortization (CF) were $60029.0 (Q1 2026), $65523.0 (Q4 2025), and $64324.0 (Q3 2025) per Business Quant data.